HIGHLIGHTS
SUMMARY
With the implementation of lung cancer screening using low-dose computed tomography worldwide, the proportion of stage IA lung cancers has increased to ≥50% compared to and amp;lt;10% in clinically diagnosed patients. Stage IA non-small-cell lung cancer (NSCLC) patients are primarily treated with surgery alone, and patients with tumors that are completely resected with negative margins typically do not receive additional treatment. Despite complete resection of the original tumor, cancer progression (recurrence, metastasis, or death) occurs in about 20% of patients with stage IA NSCLCs, and 70-90% of those . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.